Sign in to view content

Evaluating Intravitreal ANX007, a Novel C1q Inhibitor, in the Treatment of GA Secondary to AMD: The ARCHER Study

David S. Boyer, MD

Video
Published 2021

Related

Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression
Carl D. Regillo, MD
Annual Meeting Talks
2018
The Evolving Treatment of Proliferative Diabetic Retinopathy: The Diabetic Retinopathy Study to the DRCR Protocol S
Timothy W. Olsen, MD
Webinars and Journal Clubs
2016
Short-term Oral Mifepristone for the Treatment of Central Serous Chorioretinopathy (STOMP-CSC): A Placebo-Controlled Clinical Trial
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2018

Category: AMD-Non-Neovascular

See more